News Feature

Filter By:

Article Type
  • Dealmaking is returning to pre-pandemic levels with numerous billion-dollar deals being signed, many focusing on immuno-oncology and inflammation.

    • Biopharma Dealmakers
    • DealForma, LLC
    News Feature
  • Recent major antibody deals involve immune checkpoint inhibitors, antibody–drug conjugates and natural killer cell engagers for cancer.

    • Biopharma Dealmakers
    • DealForma, LLC
    News Feature
  • Since 2021, the oncology sector has seen a string of billion-dollar deals.

    • Biopharma Dealmakers
    • DealForma, LLC
    News Feature
  • With siRNA-based drugs becoming established as a therapeutic modality, large companies are engaging in the field through deals and acquisitions, and cardiovascular and metabolic diseases are among their targets.

    • Biopharma Dealmakers
    News Feature
  • The emergence of COVID-19 sparked a huge increase in the volume of infectious disease deals in 2020, but how has the market fared in the past year?

    • Biopharma Dealmakers
    • DealForma, LLC
    News Feature
  • Oncology-focused partnerships drove record-level licensing deals in 2021 as companies looked to gain access to novel therapeutic targets and platforms.

    • Mike Ward
    News Feature
  • Infectious disease diagnostics were prominent among mergers and acquisitions in the molecular diagnostics field, while financing flowed to companies developing liquid biopsy technology.

    • Beth Allan
    • Maureen Riordan
    News Feature
  • The last three months saw financings focused on nucleic acid, cell therapy and genomic medicine focused technologies as Emma Dorey explains.

    • Emma Dorey
    News Feature
  • Funding for early-stage projects and global collaborations are aiming to breathe life into the fragile ecosystem for novel antibiotics.

    • Raveena Bhambra
    News Feature
  • In the past decade, deals involving rare diseases have increased in size and value, supported by the growing number of opportunities based on novel therapeutic platforms.

    • Raveena Bhambra
    • DealForma, LLC
    News Feature